CY1120360T1 - Μεθοδος για την προωθηση της αγγειογενεσης, της αγγειωσης ή της αποκαταστασης των αγγειων, ή για την αναστολη της αγγειογενεσης ογκων - Google Patents
Μεθοδος για την προωθηση της αγγειογενεσης, της αγγειωσης ή της αποκαταστασης των αγγειων, ή για την αναστολη της αγγειογενεσης ογκωνInfo
- Publication number
- CY1120360T1 CY1120360T1 CY20171100245T CY171100245T CY1120360T1 CY 1120360 T1 CY1120360 T1 CY 1120360T1 CY 20171100245 T CY20171100245 T CY 20171100245T CY 171100245 T CY171100245 T CY 171100245T CY 1120360 T1 CY1120360 T1 CY 1120360T1
- Authority
- CY
- Cyprus
- Prior art keywords
- mir
- vasculation
- cell
- expression
- restoration
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 230000001737 promoting effect Effects 0.000 title 1
- 230000002792 vascular Effects 0.000 title 1
- 108091059456 miR-92-1 stem-loop Proteins 0.000 abstract 9
- 108091084336 miR-92-2 stem-loop Proteins 0.000 abstract 9
- 238000003780 insertion Methods 0.000 abstract 2
- 230000037431 insertion Effects 0.000 abstract 2
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000005747 tumor angiogenesis Effects 0.000 abstract 1
- 210000005166 vasculature Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Η εφεύρεση αφορά μια μέθοδο για την επίδραση της έκφρασης του miR-92 αποτελείται από τα ακόλουθα βήματα: (α) παροχή ενός κυττάρου, και (β1) Μείωση της έκφρασης του miR-92 στο κύτταρο για την προώθηση της αγγειογένεσης, της αγγείωσης ή/και της αποκατάστασης των αγγείων μέσω της εισαγωγής ενός αντίστροφου μορίου έναντι του miR-92 στο κύτταρο, ή (β2) Αύξηση της έκφρασης του miR-92 στο κύτταρο για την αναστολή της αγγειογένεσης όγκου μέσω της εισαγωγής μιας δομής στο κύτταρο, όπου η δομή περιλαμβάνει μια εκφράσιμη αλληλουχία miR-92. Περαιτέρω, η εφεύρεση αφορά μια φαρμακευτική σύνθεση, που περιλαμβάνει ένα μέσο για τη μείωση της δραστηριότητας του miR-92 ή την έκφραση σε ένα κύτταρο σε μορφή ενός αντίστροφου μορίου έναντι του miR-92,ή ένα μέσο για την αύξηση της έκφρασης του miR-92 σε ένα κύτταρο με τη μορφή μιας δομής για την έκφραση του miR-92.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102007052114A DE102007052114B4 (de) | 2007-10-30 | 2007-10-30 | Verfahren zur Modulation der Funktion, des Wachstums oder der Differenzierung einer Zelle |
| PCT/DE2008/001759 WO2009056116A1 (de) | 2007-10-30 | 2008-10-30 | Verfahren zur förderung der angiogenese, vaskularisierung oder gefässreparatur oder zur hemmung der tumorangiogenese |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1120360T1 true CY1120360T1 (el) | 2019-07-10 |
Family
ID=40375407
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171100245T CY1120360T1 (el) | 2007-10-30 | 2017-02-22 | Μεθοδος για την προωθηση της αγγειογενεσης, της αγγειωσης ή της αποκαταστασης των αγγειων, ή για την αναστολη της αγγειογενεσης ογκων |
| CY20171101283T CY1120226T1 (el) | 2007-10-30 | 2017-12-06 | Μεθοδος για την προωθηση της αγγειογενεσης, της αγγειωσης ή της αποκαταστασης των αγγειων ή για την αναστολη της αγγειογενεσης ογκων |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171101283T CY1120226T1 (el) | 2007-10-30 | 2017-12-06 | Μεθοδος για την προωθηση της αγγειογενεσης, της αγγειωσης ή της αποκαταστασης των αγγειων ή για την αναστολη της αγγειογενεσης ογκων |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US8258113B2 (el) |
| EP (3) | EP2684955B1 (el) |
| JP (4) | JP5898843B2 (el) |
| CA (1) | CA2704290C (el) |
| CY (2) | CY1120360T1 (el) |
| DE (1) | DE102007052114B4 (el) |
| DK (2) | DK2217704T3 (el) |
| ES (2) | ES2618203T3 (el) |
| HR (2) | HRP20170346T1 (el) |
| HU (2) | HUE037494T2 (el) |
| LT (2) | LT2684955T (el) |
| NO (1) | NO2684955T3 (el) |
| PL (2) | PL2217704T3 (el) |
| PT (2) | PT2217704T (el) |
| SI (2) | SI2684955T1 (el) |
| WO (1) | WO2009056116A1 (el) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20030376A1 (it) | 2003-07-31 | 2005-02-01 | Univ Roma | Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia. |
| US11660317B2 (en) | 2004-11-08 | 2023-05-30 | The Johns Hopkins University | Compositions comprising cardiosphere-derived cells for use in cell therapy |
| WO2008017473A2 (en) | 2006-08-08 | 2008-02-14 | Gunther Hartmann | Structure and use of 5' phosphate oligonucleotides |
| DE102007052114B4 (de) | 2007-10-30 | 2011-01-05 | T2Cure Gmbh | Verfahren zur Modulation der Funktion, des Wachstums oder der Differenzierung einer Zelle |
| US9738680B2 (en) | 2008-05-21 | 2017-08-22 | Rheinische Friedrich-Wilhelms-Universität Bonn | 5′ triphosphate oligonucleotide with blunt end and uses thereof |
| US9249392B2 (en) | 2010-04-30 | 2016-02-02 | Cedars-Sinai Medical Center | Methods and compositions for maintaining genomic stability in cultured stem cells |
| US9845457B2 (en) | 2010-04-30 | 2017-12-19 | Cedars-Sinai Medical Center | Maintenance of genomic stability in cultured stem cells |
| WO2012065024A1 (en) * | 2010-11-11 | 2012-05-18 | University Of Miami | Compositions, cells, kits and methods for autologous stem cell therapy |
| EP2508530A1 (en) | 2011-03-28 | 2012-10-10 | Rheinische Friedrich-Wilhelms-Universität Bonn | Purification of triphosphorylated oligonucleotides using capture tags |
| WO2013184527A1 (en) | 2012-06-05 | 2013-12-12 | Capricor, Inc. | Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy |
| CN104685056A (zh) | 2012-06-21 | 2015-06-03 | 米拉根医疗股份有限公司 | 包含锁核酸基序的基于寡核苷酸的抑制剂 |
| JP6433896B2 (ja) | 2012-08-13 | 2018-12-05 | シーダーズ−サイナイ・メディカル・センターＣｅｄａｒｓ−Ｓｉｎａｉ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ | 組織再生のためのエキソソームおよびマイクロリボ核酸 |
| EP2712870A1 (en) | 2012-09-27 | 2014-04-02 | Rheinische Friedrich-Wilhelms-Universität Bonn | Novel RIG-I ligands and methods for producing them |
| EP2759595B1 (en) * | 2013-01-24 | 2016-09-14 | Pierre Fabre Médicament S.A.S. | Composition comprising an encapsulated antagomir |
| CA2902571A1 (en) | 2013-03-15 | 2014-09-18 | MiRagen Therapeutics, Inc. | Bridged bicyclic nucleosides |
| US11439668B2 (en) | 2014-05-23 | 2022-09-13 | JangoBio, LLC | Methods to differentiate stem cells into hormone-producing cells |
| US11253549B2 (en) | 2014-05-23 | 2022-02-22 | JangoBio, LLC | Methods to rebalance the hypothalamic-pituitary-gonadal axis |
| JP6878274B2 (ja) | 2014-10-03 | 2021-05-26 | シーダーズ−サイナイ・メディカル・センターＣｅｄａｒｓ−Ｓｉｎａｉ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ | 筋ジストロフィーの処置における心筋球由来細胞およびこのような細胞によって分泌されたエキソソーム |
| US20160122762A1 (en) * | 2014-10-27 | 2016-05-05 | University Of Iowa Research Foundation | Methods of treating atherosclerosis |
| JP2018503646A (ja) | 2015-01-20 | 2018-02-08 | ミラゲン セラピューティクス， インコーポレイテッド | ｍｉＲ−９２阻害剤およびその使用 |
| WO2017123662A1 (en) | 2016-01-11 | 2017-07-20 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction |
| WO2017210652A1 (en) | 2016-06-03 | 2017-12-07 | Cedars-Sinai Medical Center | Cdc-derived exosomes for treatment of ventricular tachyarrythmias |
| CN107586784B (zh) * | 2016-07-08 | 2020-08-25 | 田小利 | 一种分离的rnasek基因及其在制备抗血管衰老药物中的应用 |
| EP3515459A4 (en) | 2016-09-20 | 2020-08-05 | Cedars-Sinai Medical Center | CELLS DERIVED FROM CARDIOSPHERES AND THEIR EXTRACELLULAR VESICLES TO DELAY OR REVERSE AGING AND AGE-RELATED DISORDERS |
| CA3059910A1 (en) | 2017-04-19 | 2018-10-25 | Cedars-Sinai Medical Center | Methods and compositions for treating skeletal muscular dystrophy |
| EP3727351A4 (en) | 2017-12-20 | 2021-10-06 | Cedars-Sinai Medical Center | MANIPULATED EXTRACELLULAR VESICLES FOR ENHANCED RELEASE INTO TISSUE |
| WO2019152549A1 (en) | 2018-02-05 | 2019-08-08 | Cedars-Sinai Medical Center | Methods for therapeutic use of exosomes and y-rnas |
| WO2019167995A1 (ja) * | 2018-02-28 | 2019-09-06 | 国立大学法人東京医科歯科大学 | 虚血病変部位特異的な遺伝子治療法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2530157B1 (en) * | 2003-07-31 | 2016-09-28 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of miRNAs |
| US7888010B2 (en) * | 2004-05-28 | 2011-02-15 | Asuragen, Inc. | Methods and compositions involving microRNA |
| US20090209621A1 (en) * | 2005-06-03 | 2009-08-20 | The Johns Hopkins University | Compositions and methods for decreasing microrna expression for the treatment of neoplasia |
| EP2369017B8 (en) * | 2006-07-13 | 2014-03-12 | The Ohio State University Research Foundation | Micro-RNA-based methods and compositions for the diagnosis and treatment of colon related diseases |
| US8466117B2 (en) * | 2006-07-28 | 2013-06-18 | The Johns Hopkins University | Compositions and methods for modulating angiogenesis |
| WO2008070082A2 (en) * | 2006-12-04 | 2008-06-12 | The Johns Hopkins University | Stem-progenitor cell specific micro-ribonucleic acids and uses thereof |
| WO2009004632A2 (en) * | 2007-07-05 | 2009-01-08 | Yeda Research And Development Co. Ltd. | Methods of identifying components of a biological pathway and use of said components in regulating diseases associated with altered cell proliferation |
| BRPI0813527A2 (pt) * | 2007-07-18 | 2014-12-30 | Univ Colorado | Expressão diferencial de micro-rnas em corações humanos que não falham versus que falham |
| DE102007052114B4 (de) | 2007-10-30 | 2011-01-05 | T2Cure Gmbh | Verfahren zur Modulation der Funktion, des Wachstums oder der Differenzierung einer Zelle |
-
2007
- 2007-10-30 DE DE102007052114A patent/DE102007052114B4/de active Active
-
2008
- 2008-10-30 EP EP13179144.4A patent/EP2684955B1/de active Active
- 2008-10-30 CA CA2704290A patent/CA2704290C/en not_active Expired - Fee Related
- 2008-10-30 PL PL08844273T patent/PL2217704T3/pl unknown
- 2008-10-30 SI SI200831894T patent/SI2684955T1/en unknown
- 2008-10-30 ES ES08844273.6T patent/ES2618203T3/es active Active
- 2008-10-30 PL PL13179144T patent/PL2684955T3/pl unknown
- 2008-10-30 HU HUE13179144A patent/HUE037494T2/hu unknown
- 2008-10-30 HU HUE08844273A patent/HUE031559T2/hu unknown
- 2008-10-30 WO PCT/DE2008/001759 patent/WO2009056116A1/de not_active Ceased
- 2008-10-30 ES ES13179144.4T patent/ES2651287T3/es active Active
- 2008-10-30 SI SI200831774A patent/SI2217704T1/sl unknown
- 2008-10-30 PT PT88442736T patent/PT2217704T/pt unknown
- 2008-10-30 LT LTEP13179144.4T patent/LT2684955T/lt unknown
- 2008-10-30 EP EP08844273.6A patent/EP2217704B1/de active Active
- 2008-10-30 NO NO13179144A patent/NO2684955T3/no unknown
- 2008-10-30 HR HRP20170346TT patent/HRP20170346T1/hr unknown
- 2008-10-30 PT PT131791444T patent/PT2684955T/pt unknown
- 2008-10-30 DK DK08844273.6T patent/DK2217704T3/en active
- 2008-10-30 US US12/739,876 patent/US8258113B2/en active Active
- 2008-10-30 LT LTEP08844273.6T patent/LT2217704T/lt unknown
- 2008-10-30 EP EP13179146.9A patent/EP2684956B1/de active Active
- 2008-10-30 JP JP2010531412A patent/JP5898843B2/ja not_active Expired - Fee Related
- 2008-10-30 DK DK13179144.4T patent/DK2684955T3/en active
-
2012
- 2012-08-08 US US13/569,786 patent/US8912158B2/en active Active
-
2014
- 2014-06-05 JP JP2014116545A patent/JP2014196317A/ja active Pending
- 2014-07-31 US US14/448,119 patent/US9279123B2/en active Active
-
2016
- 2016-02-10 US US15/040,487 patent/US9862949B2/en active Active
- 2016-06-24 JP JP2016125260A patent/JP2016199565A/ja active Pending
-
2017
- 2017-02-22 CY CY20171100245T patent/CY1120360T1/el unknown
- 2017-12-04 HR HRP20171874TT patent/HRP20171874T1/hr unknown
- 2017-12-06 CY CY20171101283T patent/CY1120226T1/el unknown
- 2017-12-14 JP JP2017239230A patent/JP2018083817A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1120360T1 (el) | Μεθοδος για την προωθηση της αγγειογενεσης, της αγγειωσης ή της αποκαταστασης των αγγειων, ή για την αναστολη της αγγειογενεσης ογκων | |
| CY1124103T1 (el) | Δοσολογικο σχημα που σχετιζεται με ενεσιμους εστερες παλιπεριδονης μακρας δρασης | |
| CY1122628T1 (el) | Χρηση αιθυλεστερα εικοσαπενταενοϊκου οξεος για θεραπεια υπερτριγλυκεριδαιμιας | |
| CY1123504T1 (el) | Αντιδοτα για τους αναστολεις του παραγοντα χα και μεθοδοι χρησεως αυτων | |
| CY1121877T1 (el) | Φαρμακευτικη συνθεση η οποια περιλαμβανει πιμοβενδανη | |
| CY1118281T1 (el) | Γελες με βαση υαλουρονικο οξυ οι οποιες συμπεριλαμβανουν υδροχλωρικη λιδοκαϊνη | |
| CY1118984T1 (el) | Παρασκευη ενεργων, ακρως φωσφορυλιωμενων, ανθρωπινων λυσοσωμικων ενζυμων σουλφατασης και χρησεις αυτων | |
| CY1120670T1 (el) | Μονοκλωνικα αντισωματα εναντι του αναστολεα μονοπατιου ιστικου παραγοντα (tfpi) | |
| CY1112831T1 (el) | Παραγωγα αζαβιρηενυlαμινοβενζοιc acid σαν παραγοντες καταστολης dhodh | |
| CY1119056T1 (el) | Παραγωγα 2',4',-διφθορο-2'-μεθυλ υποκατεστημενου νουκλεοσιδιου ως αναστολεις αντιγραφης hcv rna | |
| CY1115254T1 (el) | Φαρμακευτικα διαλυματα, διαδικασιες για την παρασκευη τους και θεραπευτικες χρησεις | |
| BR112013005134A2 (pt) | adsorção de imunopotenciadores em sais metálicos insolúveis | |
| CY1115403T1 (el) | Αλκυλαμινο-υποκατεστημενες δικυανοπυριδινες και προφαρμακα τυπου εστερα αμινοξεος αυτων | |
| NI201200038A (es) | Conjugados de niacina y ácidos grasos y sus usos | |
| EA201100358A1 (ru) | Дабигатран для чрескожной хирургической катетеризации сердца | |
| CL2011000957A1 (es) | Compuesto derivados de isoindolina sustituidos, inhibidores de citosinas tnf-a; composicion farmaceutica; utiles en el tratamiento del cancer. | |
| CY1116264T1 (el) | Αντισωματα κατα ανθρωπινης αγγειοποιητινης 2 | |
| EA200870019A1 (ru) | Лактамовые соединения и способы их применения | |
| UY31543A1 (es) | Sistema de administracion de rnai de interferencia y usos del mismo | |
| EA201390934A1 (ru) | Композиции и способы модулирования fxr | |
| EA201070421A1 (ru) | Микрорибонуклеиновые кислоты | |
| RU2009118942A (ru) | Способ стимуляции регенерации тканей | |
| CY1116494T1 (el) | Θεραπευτικη αγωγη θρομβοεμβολικων διαταραχων με ριβαροξαβανη | |
| DK1982696T3 (da) | Gel til behandling af sår | |
| CY1117000T1 (el) | Ενζυματικη αντικαρκινικη θεραπεια |